LIVN (LivaNova PLC Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by LIVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | TODD C SCHERMERHORN | Director | MIXED | — | — |
| 2026-06-17 | James Christopher Barry | Director | MIXED | — | — |
| 2026-06-17 | Francesco Bianchi | Director | MIXED | — | — |
| 2026-06-17 | Seng Stacy Enxing | Director | MIXED | — | — |
| 2026-06-17 | Ahmet Tezel | Chief Innovation Officer | MIXED | — | — |
| 2026-06-17 | PETER M WILVER | Director | MIXED | — | — |
| 2026-06-17 | Jette Nygaard-Andersen | Director | A | — | — |
| 2026-06-17 | WILLIAM A KOZY | Director | MIXED | — | — |
| 2026-06-17 | SUSAN M PODLOGAR | Director | MIXED | — | — |
| 2026-06-17 | Donald Zurbay | Director | MIXED | — | — |
| 2026-06-17 | Brooke Story | Director | MIXED | — | — |
| 2026-05-27 | Francesco Bianchi | Director | Sell | — | — |
| 2026-04-01 | Natalia Kozmina | Chief Human Resources Officer | MIXED | — | — |
| 2026-04-01 | Stephanie Bolton | President, Global Epilepsy | MIXED | — | — |
| 2026-04-01 | Vladimir Makatsaria | Chief Executive Officer | MIXED | — | — |
| 2026-04-01 | Alex Shvartsburg | Chief Financial Officer | MIXED | — | — |
| 2026-04-01 | Franco Poletti | President, Cardiopulmonary | MIXED | — | — |
| 2026-04-01 | Ahmet Tezel | Chief Innovation Officer | MIXED | — | — |
| 2026-03-13 | Franco Poletti | President, Cardiopulmonary | MIXED | — | — |
| 2025-12-17 | Michael Damon Hutchinson | SVP, CLO and Company Secretary | MIXED | — | — |
| 2025-12-17 | SUSAN M PODLOGAR | Director | MIXED | — | — |
| 2025-12-17 | Franco Poletti | President, Cardiopulmonary | MIXED | — | — |
| 2025-11-19 | Brooke Story | Director | Sell | — | — |
| 2025-09-17 | Franco Poletti | President, Cardiopulmonary | MIXED | — | — |
| 2025-09-17 | Donald Zurbay | Director | A | — | — |
| 2025-08-27 | Francesco Bianchi | Director | Sell | — | — |
| 2025-06-17 | SUSAN M PODLOGAR | Director | A | — | — |
| 2025-06-17 | Ahmet Tezel | Chief Innovation Officer | MIXED | — | — |
| 2025-06-17 | PETER M WILVER | Director | MIXED | — | — |
| 2025-06-17 | Seng Stacy Enxing | Director | MIXED | — | — |
| 2025-06-17 | Brooke Story | Director | MIXED | — | — |
| 2025-06-17 | James Christopher Barry | Director | MIXED | — | — |
| 2025-06-17 | WILLIAM A KOZY | Director | MIXED | — | — |
| 2025-06-17 | TODD C SCHERMERHORN | Director | MIXED | — | — |
| 2025-06-17 | Francesco Bianchi | Director | MIXED | — | — |
| 2025-06-17 | Sharon O'Kane | Director | MIXED | — | — |
| 2025-04-01 | Franco Poletti | President, Cardiopulmonary | MIXED | — | — |
| 2025-04-01 | Natalia Kozmina | Chief Human Resources Officer | A | — | — |
| 2025-04-01 | Alex Shvartsburg | Chief Financial Officer | MIXED | — | — |
| 2025-04-01 | Michael Damon Hutchinson | Chief Legal Officer | MIXED | — | — |
| 2025-04-01 | WILLIAM A KOZY | Director | MIXED | — | — |
| 2025-04-01 | Vladimir Makatsaria | Chief Executive Officer | MIXED | — | — |
| 2025-04-01 | Stephanie Bolton | President, Global Epilepsy | MIXED | — | — |
| 2025-04-01 | Ahmet Tezel | Chief Innovation Officer | A | — | — |
| 2024-12-17 | SUSAN M PODLOGAR | Director | A | — | — |
| 2024-12-17 | Alex Shvartsburg | Chief Financial Officer | MIXED | — | — |
| 2024-12-17 | James Christopher Barry | Director | MIXED | — | — |
| 2024-12-17 | Franco Poletti | President, Cardiopulmonary | MIXED | — | — |
| 2024-12-17 | Michael Damon Hutchinson | Chief Legal Officer | MIXED | — | — |
| 2024-12-13 | Francesco Bianchi | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,298,369 | — |
| — | 10%+ Owner | 4,963,369 | — |
| — | CEO | 111,847 | — |
| — | CEO | 93,822 | — |
| — | Chief Financial Officer | 44,647 | — |
| — | Director | 38,248 | — |
| — | General Manager, NM | 36,055 | — |
| — | Chief Financial Officer | 31,662 | — |
| — | President, Global Epilepsy | 30,566 | — |
| — | Director | 29,579 | — |
| — | President Cardiac Surgery | 28,347 | — |
| — | Chief Administrative Officer | 27,929 | — |
| — | Chief Executive Officer | 25,326 | — |
| — | Director | 23,606 | — |
| — | Chief Integration Officer | 21,495 | — |
| — | Director | 15,793 | — |
| — | SR VP Global Market Access | 15,740 | — |
| — | Pres Cardiac Rhythm Mgmt | 14,444 | — |
| — | Chief Human Resources Officer | 13,779 | — |
| — | SR VP Genl Counsel & Secretary | 13,051 | — |
| — | Director | 12,714 | — |
| — | Director | 12,619 | — |
| — | President, Cardiopulmonary | 12,344 | — |
| — | Director | 11,304 | — |
| — | President Intercontinental | 10,948 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LIVN quote page; the site-wide leaderboard is on the insider transactions hub.